APR 25, 2019

Infectious Disease 2019

Our Inaugural Infectious Disease Virtual Event is now available On-Demand! The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing.

Topic's for this years event included:

Stories and Lessons of the Past
Current Challenges and Controversies
Emerging Tools and Methods

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 14 credits.

Use #LRinfectious to follow the conversation!

Speakers

Colleen Kraft, MD, MSc

Associate Professor, Pathology & Laboratory Medicine, Emory University School of Medicine
BIOGRAPHY
Stephen S. Morse, PhD, FAAM, F.A.C.E.

Professor of Epidemiology, Director, Infectious Disease Epidemiology Certificate, Columbia University, Mailman School of Public Health
BIOGRAPHY
Krishnan Allampallam, PhD

Global Marketing Director, Chembio Diagnostic Systems
BIOGRAPHY
Meredith Ashby, PhD

Director, Market Strategy for Microbial and Cancer Genomics, Pacific Biosciences
BIOGRAPHY
Matthew Flegal, BS, SRS

Senior Manager InVivo Sciences, Charles River
BIOGRAPHY
Paul Lambotte, PhD

Vice President, Research & Development, Chembio Diagnostic Systems
BIOGRAPHY
Christina A. Muzny, MD, MSPH, FACP

Associate Professor of Medicine and Epidemiology, Division of Infectious Diseases, University of Alabama at Birmingham
BIOGRAPHY
Faramarz Valafar, PhD

Director & Professor, Biomedical Informatics Research Center, Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, San Diego State University
BIOGRAPHY
Corey T. Watson, PhD

Assistant Professor, Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine
BIOGRAPHY

Show Resources

You May Also Like

SEP 06, 2022 6:00 AM PDT

Microbiology Virtual Week 2022

LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 8th Annu...

NOV 10, 2021 6:00 AM PST

Clinical Diagnostics & Research 2021

Twelve years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event...

NOV 09, 2022 6:00 AM PST

Clinical Diagnostics & Research 2022

Thirteen years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2022 Clinical Diagnostics and Research Virtual Event will again bring together clinic...

MAR 23, 2022 6:00 AM PDT

Cannabis Sciences 2022

LabRoots is pleased to announce the 5th Annual 2021 Cannabis Sciences Virtual Event . LabRoots will host the event on March 23, 2022. The Cannabis Sciences planning committee will be plannin...

OCT 04, 2021 11:00 AM EDT

8th Annual Conference: SBI2 High Content

To SBI2 members and sponsors, On behalf of the Society of Biomolecular Imaging and Informatics Board of Directors, I am pleased to announce the 8th annual High Content conference which will...

APR 19, 2022 6:00 AM PDT

Genetics Virtual Week 2022

LabRoots is excited to announce our 10th Annual Genetics Virtual Week held on April 19-21, 2022! Genetics Virtual Week 2022 will offer a multi-day content-rich program combining stellar expe...

Agenda

Download Agenda

APR 25, 2019 1:30 PM PDT

In Vivo Models for Infectious Disease Research Through the Years

Matthew Flegal, BS, SRS

Senior Manager InVivo Sciences, Charles River
BIOGRAPHY

Over the past 25 years many advances in techniques have been incorporated into infectious disease research. From genetically modified animals to advances in basic techniques that improve results much has changed. However, many other core principles are just as critical now as they were then and tend to be forgotten in the rush to incorporate new technologies. This presentation will discuss what has changed in the last quarter century for in vivo research including new technologies and techniques as well as point out some critical concepts that deserve to remain in consideration.

Learning Objectives:

1. Demonstrate the need for a high level of technical skill and understanding to generate high quality data while maintaining the appropriate welfare of our animals
2. Identify key components for high level study execution

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 12:00 PM PDT

Diagnosis and Treatment of Tuberculosis, a Case Study in Challenges and Threats Posed by Infectious Diseases

Faramarz Valafar, PhD

Director & Professor, Biomedical Informatics Research Center, Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, San Diego State University
BIOGRAPHY

Tuberculosis has killed more than one billion people in the last 200 years. It is the oldest and the deadliest human pathogen, recently surpassing HIV. Its adaptation to host and drug pressures is remarkable given its slow rate of growth and provides a moving target in molecular epidemiology of the disease. In this talk we will discuss the epidemiology of the disease, the challenges that the pathogen offers in its adaptation, and the challenges faced in the diagnosis and treatment of the disease. We will discuss the advantages and disadvantages of various diagnostics platforms and outline some exciting new developments on the diagnostics and prognostics fronts.

Learning Objectives:

1. Epidemiology of tuberculosis
2. Diagnostic approaches for detection of antibiotic resistance

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 10:30 AM PDT

Advances in Point-Of-Care Testing for Infectious Diseases

Krishnan Allampallam, PhD, Paul Lambotte, PhD

Sponsored By: Chembio

Point-of-care testing (POCT) is diagnostic testing at the time and place of patient care in a physician’s office, an ambulance, a mobile clinic, at home or in hospital. Rapid POC testing yields actionable results and rapid treatment of patients. Until now, POC tests based on lateral flow technology have suffered of limitations in sensitivity, specificity, the lack of multiplexing and the questionable reliability of results obtained visually by the users. To address these limitations, Chembio has developed an advanced rapid POC testing solution, the DPP® System combining its Dual Path Platform (DPP®) disposable cartridges with its optical analyzer (DPP® Reader). The DPP® System provides users with a complete solution for rapid testing at the Point of Care. The DPP® System requires one small sample from the patient, minimum hands-on time, short turn-around time, and provides multiple results in one operation, free from human bias. During the webinar “Advances in POC Testing for infectious diseases”, we will introduce the advanced DPP® technology, the optical analyzer, and demonstrate the power of the DPP® Systems in detecting multiple biomarkers at the Point of Care.

Learning Objectives:

1. Current needs and status of POC diagnostics in infectious diseases
2. What is DPP technology and how it differs from the current lateral flow technology
3. Application of DPP technology in multiplex testing
4. How the combination of DPP technology and a hand held digital reader in POC testing improves testing accuracy

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar

Krishnan Allampallam, PhD
Global Marketing Director, Chembio Diagnostic Systems
BIOGRAPHY

Paul Lambotte, PhD
Vice President, Research & Development, Chembio Diagnostic Systems
BIOGRAPHY
APR 25, 2019 10:30 AM PDT

Overcoming Complexity to Elucidate the Role of Immunoglobulin Polymorphism in the Functional Antibody Response

Corey Watson, PhD

Assistant Professor, Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine
BIOGRAPHY

Recent evidence indicates that the immunoglobulin (IG) gene loci reside within the most complex and variable regions of the human genome, characterized by elevated levels of single nucleotide and gene copy number variants. This unique locus architecture has hindered the comprehensive characterization of polymorphisms in these regions, particularly using standard, short-read and array-based high-throughput genomic methods. As a result, our appreciation of the extent of haplotype variation across human populations, and the role of IG polymorphism in the immune response remains limited. This presentation will discuss efforts currently underway to establish improved genomic resources and tools that will facilitate large-scale characterization of IG genetic diversity as a means to leverage this information to improve our understanding of the functional antibody response in disease and relevant clinical phenotypes.

Learning Objectives:

1. Appreciate the complexity of the human immunoglobulin gene regions and the need for improved genomic resources and tools.
2. Understand the importance of immunoglobulin genetic variation in the antibody response and antibody-related phenotypes.

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 9:00 AM PDT

Keynote Presentation: The Next Pandemic

Stephen S. Morse, PhD, FAAM, F.A.C.E.

Professor of Epidemiology, Director, Infectious Disease Epidemiology Certificate, Columbia University, Mailman School of Public Health
BIOGRAPHY

“Emerging infections” are those that appear suddenly or are rapidly increasing in incidence or geographic range (e.g., HIV/AIDS, Ebola, SARS, Middle East Respiratory Syndrome [MERS], H5N1 avian influenza, pandemic influenza, Zika). Most are pathogens from other species that acquire opportunities to come in contact with humans and spread (often as a result of such factors as changes in ecology and land use, increasing urbanization, and human movement). A pandemic is an epidemic that spreads to cover a broad geographic range. Despite progress in identifying the underlying factors (or “drivers”) and improvements in early warning, no emerging infection or pandemic to date has been correctly predicted before its appearance in humans. In two of the most recent epidemics, Ebola in West Africa and Zika in the Americas, the first outbreaks were initially discounted. Before the recent reports of neurological effects, Zika, a mosquito-borne virus that came to Brazil from the Pacific Islands only two years ago and had been circulating in Africa far longer, was considered a mild disease and little cause for concern. By contrast, Ebola's lethality has been legendary since its first identification in 1976, but an epidemic with over 11,000 fatalities seemed inconceivable. Such surprises demonstrate that population density, and host social and biological factors, likely play as important a role in the development of pandemics as characteristics of the pathogen, and should serve to warn against complacency. Our current approach is reactive. Although we have the capability to develop more effective systems to anticipate and prevent emerging infections and pandemics, much more needs to be done. Many effective public health measures, such as immunization and mosquito control, often become victims of their own success and are not sustained. As urbanization increases worldwide, effective and sustainable early warning and response remain ever more essential.

Learning Objectives:

1. Define and distinguish an emerging infection and a pandemic
2. Assess probable future pandemic risks and how they might be prevented

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 7:30 AM PDT

Keynote Presentation: Ebola Virus Disease - 2019 and Beyond

Colleen Kraft, MD, MSc

Associate Professor, Pathology & Laboratory Medicine, Emory University School of Medicine
BIOGRAPHY

The Ebola virus disease outbreak in West Africa in 2014-2016 was the largest of its kind in history. This was the first outbreak that involved a randomized clinical trial for therapeutics, and the first where affected individuals were repatriated to other countries. Knowledge regarding Ebola virus disease dramatically increased during this outbreak, and more was learned clinically, epidemiologically and scientifically. This lecture describes the advances from this outbreak in the context of the current outbreak that is occurring in the Democratic Republic of the Congo.

Learning Objectives:

1. Know the current status of the Ebola outbreak in the Democratic Republic of the Congo
2. Understand the current state of therapeutics for Ebola virus disease

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 6:00 AM PDT

Is Bacterial Vaginosis a Sexually Transmitted Infection?

Christina Muzny, MD, MSPH, FACP

Associate Professor of Medicine and Epidemiology, Division of Infectious Diseases, University of Alabama at Birmingham
BIOGRAPHY

Despite over 60+ years of research, the etiology of bacterial vaginosis (BV), the most common vaginal infection, remains controversial. Epidemiological data strongly suggest that BV is acquired via sexual transmission. This presentation will review pertinent epidemiological data regarding BV, particularly as it relates to sexual transmission. It will also discuss current hypotheses regarding the etiology of BV.

Learning Objectives:

1. Review the epidemiology of bacterial vaginosis (BV), particularly as it relates to sexual transmission
2. Discuss current hypotheses regarding the etiology of BV

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 6:00 AM PDT

Long-Read Sequencing and Infectious Disease: New Insights Into Longstanding Challenges

Meredith Ashby, PhD

Director, Market Strategy for Microbial and Cancer Genomics, Pacific Biosciences
BIOGRAPHY
Sponsored By: PacBio

To reduce the global burden diseases causes by infectious disease, including parasites and bacteria, scientists need better information about mechanisms of virulence, immune evasion, and drug resistance, as well as new insights into parasite and pathogen vector biology and life cycles. One of the longstanding challenges in infectious disease has been the lack of high-quality reference genomes. Parasite genomes in particular have been highly fragmented, as the telomeric regions of their chromosomes are dense with highly homologous genes that cannot be resolved with short read sequencing. Recent developments in genome sequencing, however, are helping researchers overcome this barrier. Recently, highly contiguous genome assemblies of Plasmodium falciparum, Aedes aegypti, and multiple trypanosomes have become available. The number of reference genomes for bacteria that cause infectious disease is similarly expanding rapidly. Join Dr. Ashby as she discusses now these new resources are already yielding new biological insights into critical questions in infectious disease research, including how parasites evade the immune system add how pathogens are adapting to evolutionary pressures.

Learning Objectives:

1. Understand how the structure of parasite genomes facilitates immune evasion and rapid adaptation while at the same time creating challenges for high-quality genome assembly.
2. Discuss how long-read sequencing and high-quality references facilitate the identification of genomic changes linked to selective pressure, either directly or in conjunction with short read data.

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar

Current Challenges and Controversies
APR 25, 2019 6:00 AM PDT

Is Bacterial Vaginosis a Sexually Transmitted Infection?

Christina Muzny, MD, MSPH, FACP

Associate Professor of Medicine and Epidemiology, Division of Infectious Diseases, University of Alabama at Birmingham
BIOGRAPHY

Despite over 60+ years of research, the etiology of bacterial vaginosis (BV), the most common vaginal infection, remains controversial. Epidemiological data strongly suggest that BV is acquired via sexual transmission. This presentation will review pertinent epidemiological data regarding BV, particularly as it relates to sexual transmission. It will also discuss current hypotheses regarding the etiology of BV.

Learning Objectives:

1. Review the epidemiology of bacterial vaginosis (BV), particularly as it relates to sexual transmission
2. Discuss current hypotheses regarding the etiology of BV

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 9:00 AM PDT

Keynote Presentation: The Next Pandemic

Stephen S. Morse, PhD, FAAM, F.A.C.E.

Professor of Epidemiology, Director, Infectious Disease Epidemiology Certificate, Columbia University, Mailman School of Public Health
BIOGRAPHY

“Emerging infections” are those that appear suddenly or are rapidly increasing in incidence or geographic range (e.g., HIV/AIDS, Ebola, SARS, Middle East Respiratory Syndrome [MERS], H5N1 avian influenza, pandemic influenza, Zika). Most are pathogens from other species that acquire opportunities to come in contact with humans and spread (often as a result of such factors as changes in ecology and land use, increasing urbanization, and human movement). A pandemic is an epidemic that spreads to cover a broad geographic range. Despite progress in identifying the underlying factors (or “drivers”) and improvements in early warning, no emerging infection or pandemic to date has been correctly predicted before its appearance in humans. In two of the most recent epidemics, Ebola in West Africa and Zika in the Americas, the first outbreaks were initially discounted. Before the recent reports of neurological effects, Zika, a mosquito-borne virus that came to Brazil from the Pacific Islands only two years ago and had been circulating in Africa far longer, was considered a mild disease and little cause for concern. By contrast, Ebola's lethality has been legendary since its first identification in 1976, but an epidemic with over 11,000 fatalities seemed inconceivable. Such surprises demonstrate that population density, and host social and biological factors, likely play as important a role in the development of pandemics as characteristics of the pathogen, and should serve to warn against complacency. Our current approach is reactive. Although we have the capability to develop more effective systems to anticipate and prevent emerging infections and pandemics, much more needs to be done. Many effective public health measures, such as immunization and mosquito control, often become victims of their own success and are not sustained. As urbanization increases worldwide, effective and sustainable early warning and response remain ever more essential.

Learning Objectives:

1. Define and distinguish an emerging infection and a pandemic
2. Assess probable future pandemic risks and how they might be prevented

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 10:30 AM PDT

Overcoming Complexity to Elucidate the Role of Immunoglobulin Polymorphism in the Functional Antibody Response

Corey Watson, PhD

Assistant Professor, Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine
BIOGRAPHY

Recent evidence indicates that the immunoglobulin (IG) gene loci reside within the most complex and variable regions of the human genome, characterized by elevated levels of single nucleotide and gene copy number variants. This unique locus architecture has hindered the comprehensive characterization of polymorphisms in these regions, particularly using standard, short-read and array-based high-throughput genomic methods. As a result, our appreciation of the extent of haplotype variation across human populations, and the role of IG polymorphism in the immune response remains limited. This presentation will discuss efforts currently underway to establish improved genomic resources and tools that will facilitate large-scale characterization of IG genetic diversity as a means to leverage this information to improve our understanding of the functional antibody response in disease and relevant clinical phenotypes.

Learning Objectives:

1. Appreciate the complexity of the human immunoglobulin gene regions and the need for improved genomic resources and tools.
2. Understand the importance of immunoglobulin genetic variation in the antibody response and antibody-related phenotypes.

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 12:00 PM PDT

Diagnosis and Treatment of Tuberculosis, a Case Study in Challenges and Threats Posed by Infectious Diseases

Faramarz Valafar, PhD

Director & Professor, Biomedical Informatics Research Center, Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, San Diego State University
BIOGRAPHY

Tuberculosis has killed more than one billion people in the last 200 years. It is the oldest and the deadliest human pathogen, recently surpassing HIV. Its adaptation to host and drug pressures is remarkable given its slow rate of growth and provides a moving target in molecular epidemiology of the disease. In this talk we will discuss the epidemiology of the disease, the challenges that the pathogen offers in its adaptation, and the challenges faced in the diagnosis and treatment of the disease. We will discuss the advantages and disadvantages of various diagnostics platforms and outline some exciting new developments on the diagnostics and prognostics fronts.

Learning Objectives:

1. Epidemiology of tuberculosis
2. Diagnostic approaches for detection of antibiotic resistance

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
Emerging Tools and Methods
APR 25, 2019 6:00 AM PDT

Long-Read Sequencing and Infectious Disease: New Insights Into Longstanding Challenges

Meredith Ashby, PhD

Director, Market Strategy for Microbial and Cancer Genomics, Pacific Biosciences
BIOGRAPHY
Sponsored By: PacBio

To reduce the global burden diseases causes by infectious disease, including parasites and bacteria, scientists need better information about mechanisms of virulence, immune evasion, and drug resistance, as well as new insights into parasite and pathogen vector biology and life cycles. One of the longstanding challenges in infectious disease has been the lack of high-quality reference genomes. Parasite genomes in particular have been highly fragmented, as the telomeric regions of their chromosomes are dense with highly homologous genes that cannot be resolved with short read sequencing. Recent developments in genome sequencing, however, are helping researchers overcome this barrier. Recently, highly contiguous genome assemblies of Plasmodium falciparum, Aedes aegypti, and multiple trypanosomes have become available. The number of reference genomes for bacteria that cause infectious disease is similarly expanding rapidly. Join Dr. Ashby as she discusses now these new resources are already yielding new biological insights into critical questions in infectious disease research, including how parasites evade the immune system add how pathogens are adapting to evolutionary pressures.

Learning Objectives:

1. Understand how the structure of parasite genomes facilitates immune evasion and rapid adaptation while at the same time creating challenges for high-quality genome assembly.
2. Discuss how long-read sequencing and high-quality references facilitate the identification of genomic changes linked to selective pressure, either directly or in conjunction with short read data.

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 10:30 AM PDT

Advances in Point-Of-Care Testing for Infectious Diseases

Krishnan Allampallam, PhD, Paul Lambotte, PhD

Sponsored By: Chembio

Point-of-care testing (POCT) is diagnostic testing at the time and place of patient care in a physician’s office, an ambulance, a mobile clinic, at home or in hospital. Rapid POC testing yields actionable results and rapid treatment of patients. Until now, POC tests based on lateral flow technology have suffered of limitations in sensitivity, specificity, the lack of multiplexing and the questionable reliability of results obtained visually by the users. To address these limitations, Chembio has developed an advanced rapid POC testing solution, the DPP® System combining its Dual Path Platform (DPP®) disposable cartridges with its optical analyzer (DPP® Reader). The DPP® System provides users with a complete solution for rapid testing at the Point of Care. The DPP® System requires one small sample from the patient, minimum hands-on time, short turn-around time, and provides multiple results in one operation, free from human bias. During the webinar “Advances in POC Testing for infectious diseases”, we will introduce the advanced DPP® technology, the optical analyzer, and demonstrate the power of the DPP® Systems in detecting multiple biomarkers at the Point of Care.

Learning Objectives:

1. Current needs and status of POC diagnostics in infectious diseases
2. What is DPP technology and how it differs from the current lateral flow technology
3. Application of DPP technology in multiplex testing
4. How the combination of DPP technology and a hand held digital reader in POC testing improves testing accuracy

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar

Krishnan Allampallam, PhD
Global Marketing Director, Chembio Diagnostic Systems
BIOGRAPHY

Paul Lambotte, PhD
Vice President, Research & Development, Chembio Diagnostic Systems
BIOGRAPHY
Stories and Lessons of the Past
APR 25, 2019 7:30 AM PDT

Keynote Presentation: Ebola Virus Disease - 2019 and Beyond

Colleen Kraft, MD, MSc

Associate Professor, Pathology & Laboratory Medicine, Emory University School of Medicine
BIOGRAPHY

The Ebola virus disease outbreak in West Africa in 2014-2016 was the largest of its kind in history. This was the first outbreak that involved a randomized clinical trial for therapeutics, and the first where affected individuals were repatriated to other countries. Knowledge regarding Ebola virus disease dramatically increased during this outbreak, and more was learned clinically, epidemiologically and scientifically. This lecture describes the advances from this outbreak in the context of the current outbreak that is occurring in the Democratic Republic of the Congo.

Learning Objectives:

1. Know the current status of the Ebola outbreak in the Democratic Republic of the Congo
2. Understand the current state of therapeutics for Ebola virus disease

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar
APR 25, 2019 1:30 PM PDT

In Vivo Models for Infectious Disease Research Through the Years

Matthew Flegal, BS, SRS

Senior Manager InVivo Sciences, Charles River
BIOGRAPHY

Over the past 25 years many advances in techniques have been incorporated into infectious disease research. From genetically modified animals to advances in basic techniques that improve results much has changed. However, many other core principles are just as critical now as they were then and tend to be forgotten in the rush to incorporate new technologies. This presentation will discuss what has changed in the last quarter century for in vivo research including new technologies and techniques as well as point out some critical concepts that deserve to remain in consideration.

Learning Objectives:

1. Demonstrate the need for a high level of technical skill and understanding to generate high quality data while maintaining the appropriate welfare of our animals
2. Identify key components for high level study execution

SEE ABSTRACT HIDE ABSTRACT

Watch Webinar

Posters

Speakers

Colleen Kraft, MD, MSc

Associate Professor, Pathology & Laboratory Medicine, Emory University School of Medicine

BIOGRAPHY
Stephen S. Morse, PhD, FAAM, F.A.C.E.

Professor of Epidemiology, Director, Infectious Disease Epidemiology Certificate, Columbia University, Mailman School of Public Health

BIOGRAPHY
Krishnan Allampallam, PhD

Global Marketing Director, Chembio Diagnostic Systems

BIOGRAPHY
Meredith Ashby, PhD

Director, Market Strategy for Microbial and Cancer Genomics, Pacific Biosciences

BIOGRAPHY
Matthew Flegal, BS, SRS

Senior Manager InVivo Sciences, Charles River

BIOGRAPHY
Paul Lambotte, PhD

Vice President, Research & Development, Chembio Diagnostic Systems

BIOGRAPHY
Christina A. Muzny, MD, MSPH, FACP

Associate Professor of Medicine and Epidemiology, Division of Infectious Diseases, University of Alabama at Birmingham

BIOGRAPHY
Faramarz Valafar, PhD

Director & Professor, Biomedical Informatics Research Center, Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, San Diego State University

BIOGRAPHY
Corey T. Watson, PhD

Assistant Professor, Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine

BIOGRAPHY

General Labroots Questions

email support@labroots.com

Virtual Events and Webinars

Supported Configurations

Operating System	Internet Explorer	Firefox	Chrome	Safari
Vista	IE8+	FF10+	Chrome15+
Windows 7	IE8+	FF10+	Chrome15+
Windows 8	IE10	FF10+	Chrome15+
Mac OS X		FF10+	Chrome15+	Safari5.1+

Cookie settings: session cookies enabled
Browser configuration must have JavaScript enabled
Adobe Flash player 10.2 or later

To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

Internet Connection

A minimum of 100Kbps is recommended for audio-only events
A minimum of 300Kbps is recommended for speaker on-video events

Computer Equipment

Screen Resolution: Minimum 1024x768
Video Card: 65,000 colors minimum
Sound card and speakers (or headphones) for hearing webcast in full format
Audio Card: 16-bit minimum
RAM: 512MB of free RAM

Firewall Protocol

HTTP on port 80 or HTTPS on port 443
Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
RTMPE (RTMP encrypted) on ports 1935, 80 or 443

Work-At-Home Attendees

If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

For A Seamless Experience

Registration is required for most events
Adobe Flash Player is needed to view webinar videos
Self Test your system compatibility ahead of time

When using a mobile device, FREE Mobile Apps are available:

- For viewing Webinars:

iPhone/iPad, download the Webcast Studio App
Android device, download the Webcast Studio App

- For viewing Virtual Events

iPhone/iPad, download the Virtual Environments App
Android, download the Virtual Environments App

Attendee Guide

To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

Virtual Event and Webinar Support:

Email: support@labroots.com
Webpage: About Virtual Events

Continuing Education (CME/CE) Support

Phone: +1-714-930-3518
Email: CE@labroots.com
Webpage: Continuing Education CME/CE Credits

Demographics

Specialty

Molecular Biology

Microbiology

Infectious Disease

Laboratory Testing

Immunology

Molecular Diagnostics

Clinical Diagnostics

Cancer Research

Genetics

Cell Biology

Clinical Research

Biotechnology

Medicine

Diagnostics

Biochemistry

Geography

North America57%

Europe15%

Asia14%

Africa6%

South America5%

Oceania1%

Registration Source

Website Visitors62%

Email Promotions26%

Social Media Promotions6%

WAVE Newsletter Promotion4%

Other2%

Job Title

Student16%

Medical Laboratory Technician15%

Educator/Faculty9%

Facility/Department Manager9%

Research Scientist9%

Executive8%

Lab Management8%

Clinical Laboratory Scientist8%

Medical Doctor/Specialist6%

Scientist4%

Microbiologist3%

Veterinarian2%

Biologist1%

Marketing/Sales1%

QC/QA1%

Post Doc1%

Organization

Academic Institution22%

Hospital19%

Clinical Laboratory11%

Biotech Company6%

Government5%

Research Institute4%

Medical School4%

Medical Center3%

Life Science Company2%

Pharmaceutical Company2%

Diagnostic Company2%

Medical Device Company2%

Government/public1%

Non-Profit Organization1%

Other5%

Infectious Disease 2019

Colleen Kraft, MD, MSc

Stephen S. Morse, PhD, FAAM, F.A.C.E.

Krishnan Allampallam, PhD

Meredith Ashby, PhD

Matthew Flegal, BS, SRS

Paul Lambotte, PhD

Christina A. Muzny, MD, MSPH, FACP

Faramarz Valafar, PhD

Corey T. Watson, PhD